Experimental weight-loss drug retatrutide delivered promising Phase 3 results in adults with type 2 diabetes. The highest dose achieved an average 18.8% weight reduction and improved blood sugar and cardiometabolic markers. Nausea and diarrhoea were common side effects. Eli Lilly’s drug remains unapproved and must undergo regulatory review before use.
Telangana
Weight Loss Drug Retatrutide Shows Strong Results
